Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Medtronic plc

MDT

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, surgical robots, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Last trade $102.95
Day change +$0.07 (+0.07%)
Day range $102.37 – $103.79
Volume 2,753,259
Market cap $131.60B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$131.6B
Price / earnings
25.16×
Price / book
2.62×
Price / sales
3.51×
EV / sales
4.21×
EV / EBITDA
15.74×

Profitability

Earnings per share
$4.09
Return on assets
5.61%
Return on equity
10.41%
Dividend yield
2.77%

Liquidity and leverage

Debt / equity
0.56×
Current ratio
2.07×
Quick ratio
1.54×
Cash ratio
0.14×

Cash flow

Price / cash flow
16.38×
Price / free cash flow
21.46×
Free cash flow
$6.13B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MDT, quarterly periods
Line itemQ1 FY2027 Jul 31, 2026Q4 FY2026 Apr 24, 2026Q3 FY2026 Jan 23, 2026Q2 FY2026 Oct 24, 2025Q1 FY2026 Jul 25, 2025Q4 FY2025 Apr 25, 2025Q3 FY2025 Jan 24, 2025Q2 FY2025 Oct 25, 2024
Revenue$9.76B$9.81B$9.02B$8.96B$8.58B$8.93B$8.29B$8.4B
Cost of revenue$3.42B$3.4B$3.26B$3.06B$3B$3.15B$2.78B$2.95B
Gross profit$6.34B$6.41B$5.76B$5.9B$5.58B$5.78B$5.51B$5.46B
Selling, general and administrative$3.2B$3.06B$2.96B$2.97B$2.81B$2.72B$2.72B$2.76B
Research and development$771M$671M$722M$754M$726M$684M$675M$697M
Total operating expenses$4.58B$4.66B$4.26B$4.19B$4.13B$4.31B$3.87B$3.9B
Operating income$1.76B$1.75B$1.5B$1.71B$1.44B$1.47B$1.64B$1.56B
Interest expense-$186M-$176M-$181M-$181M-$176M-$174M-$179M-$209M
Income before taxes$1.77B$1.83B$1.4B$1.6B$1.3B$1.26B$1.54B$1.56B
Income taxes$289M$575M$254M$215M$255M$199M$237M$281M
Net income$1.48B$1.26B$1.15B$1.38B$1.05B$1.06B$1.3B$1.28B
Net income attributable to common shareholders$1.47B$1.24B$1.14B$1.37B$1.04B$1.06B$1.29B$1.27B
EBITDA$2.57B$2.69B$2.32B$2.46B$2.26B$2.78B$2.37B$2.27B
Basic earnings per share$1.15$0.97$0.89$1.07$0.81$0.82$1.01$0.99
Diluted earnings per share$1.14$0.97$0.89$1.07$0.81$0.82$1.01$0.99

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nerve Repair and Regeneration - Global Market Share Analysis, Industry Trends, Growth Forecasts, 2026-2031 | AI-Enabled Devices and Biomaterials Fuel 11.96% CAGR

The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.

Zacks Investment Research

ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?

Intuitive Surgical delivered robust Q3 2026 results with adjusted EPS up 25% to $3 and revenue growth of 22% to $3.1 billion, driven by expanding robotic platform adoption and improved operating efficiency. The company maintains a 42% operating margin while investing heavily in R&D for AI features and new platforms. However, reported GAAP net income declined due to a $450 million litigation settlement. Peer medical device makers Stryker and Medtronic also posted strong earnings growth, though facing headwinds from procedure volume pressures and supply constraints.

Zacks Investment Research

MDT Q2 Earnings Preview: Will Cardiovascular Performance Lift Results?

Medtronic is expected to report Q2 fiscal 2027 results on November 24, with revenues projected to grow 5.7% to $9.47 billion and EPS estimated at $1.34 (down 1.5% YoY). The Cardiovascular segment is expected to drive growth at 9.6%, supported by cardiac ablation, CRM, and structural heart products. Diabetes revenues are projected to grow 12.9% following the MiniMed separation. However, the company has a negative Earnings ESP of -0.75%, suggesting limited upside surprise potential.

Zacks Investment Research

FitLife Brands Inc. (FTLF) Q3 Earnings and Revenues Lag Estimates

FitLife Brands reported quarterly earnings of $0.19 per share, missing the consensus estimate of $0.25 and representing a -24% earnings surprise. Revenue also fell short of expectations at $25.62 million versus the estimate. The stock has significantly underperformed the market, declining 47.9% year-to-date compared to the S&P 500's 10.5% gain. With a Zacks Rank #3 (Hold) rating and the Medical-Products industry in the bottom 43% of performance, the outlook remains uncertain pending management commentary.

The Motley Fool

5 Dividend Stocks to Buy and Hold Forever

The article recommends five dividend stocks suitable for long-term buy-and-hold investors: Johnson & Johnson, Medtronic, Procter & Gamble, Federal Realty Investment Trust, and Realty Income. All five companies have strong dividend track records with at least 32 years of consecutive annual increases, combined with well-run underlying businesses that generate reliable income streams.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 25, 2026$0.72Oct 16, 2026recurring
Jun 26, 2026$0.72Jul 17, 2026recurring
Mar 27, 2026$0.71Apr 17, 2026recurring
Dec 26, 2025$0.71Jan 16, 2026recurring
Sep 26, 2025$0.71Oct 17, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.